It is being studied in clinical trials, and Lilly has reported positive Phase 3 topline results, but investigational results are not the same as FDA approval
The therapeutic potential of GLP-1 receptor biased agonism
Several other trials are assessing the safety and efficacy of tirzepatide in improving different cardiometabolic complications such as OSA, MASH and heart failure with preserved ejection fraction (HFpEF) (NCT05412004, NCT04166773, NCT 04847557) [16]
Insulin and IGF-1 signaling GLP-1 medications improve insulin sensitivity, which is one of their major metabolic benefits
Orforglipron, the easier-to-use alternative to injectable weight-loss and diabetes medications, is a promising new tool with improved convenience for providers and patients
CrossRef Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management Hamza A